India Slashes Weight-Loss Drug Prices After Patent Expires

Millions of people struggling with obesity just got a lifeline as India prepares to flood the market with low-cost versions of weight-loss drugs like Ozempic. After semaglutide's patent expired on March 20, 2026, at least 50 generic brands are ready to launch, potentially cutting monthly treatment costs by 75 percent.

The timing couldn't be better. In Mumbai, endocrinologist Nadeem Rais currently treats 80 patients with weight-loss injections, but turns away many more who can't afford the 15,000 to 22,000 rupees ($161 to $236) monthly price tag. "When generics come out and prices drop, that could go up to 200 easily," he told reporters.

His colleague Sunera Ghai sees the same pattern daily. Demand is sky-high, but most patients view these medications as "truly a luxury item at this point." That's about to change dramatically.

Major Indian pharmaceutical companies, including Zydus Lifesciences, have announced "Day 1" launches, meaning generic versions could hit pharmacies this weekend. Industry experts estimate treatment costs will drop to around 5,000 rupees ($60) monthly, making them accessible to middle-class families across India and beyond.

The impact extends far beyond India's borders. As the world's largest supplier of generic medicines, India ships more than half of Africa's pharmaceutical needs. Countries across the Global South, where obesity rates are climbing but treatment remains unaffordable, could soon access these life-changing medications.

By year's end, semaglutide patents will expire in 10 countries representing 48 percent of the global obesity burden, including Brazil, China, South Africa, Turkey, and Canada. Dr. Reddy's Laboratories plans to launch its Canadian version by May 2026.

The Ripple Effect

India's weight-loss drug market has already grown tenfold in five years to $153 million, and could exceed half a billion by 2030. But the real victory isn't measured in market size. It's counted in lives changed.

Sukant Mangal, 46, lost nearly 30 pounds in eight months on treatment but knows many friends who quit halfway through when facing seven to eight months of $214 monthly payments. "Had it been cheaper, it would've been much easier," he said.

Simon Barquera, president of the World Obesity Federation, calls the development significant but emphasizes that medication alone won't solve the crisis. "Obesity is a complex, chronic disease," he noted, stressing the importance of prevention and healthier environments alongside treatment.

For Mumbai weight-loss clinic operator Swati Pradhan, who's watched patients struggle with impossible choices between treatment and other necessities, the arrival of generics represents more than market competition. It's access to dignity and health becoming a right rather than a luxury.

Doctors across Mumbai are already preparing their clinics for an expected surge in new patients, a problem they're genuinely excited to have.